(Gerd Altmann, Pixabay)
9 November 2017. Memorial Sloan Kettering Cancer Center in New York is collaborating with health care analytics company Cota Inc. to offer more precise care strategies for patients. Financial details of the multi-year agreement were not disclosed.
Cota Inc., also in New York, offers its Cota Nodal Address system that generates a precise digital classification scheme for diseases, incorporating data from patients’ electronic clinical health records and genomic analysis to produce fine-grained disease categories. Each of these precise categories is then uniquely identified, making it possible to apply these disease groupings to collections of patients with similar characteristics. In this way, says the company, the Cota Nodal Address system acts as a bridge between precision medicine and population health.
The agreement calls for Memorial Sloan Kettering to provide de-identified clinical records for Cota’s Nodal Address or CNA System. The system will then produce data sets that combine clinical and genomic information for Memorial Sloan Kettering clinical staff, as well as support the cancer center’s research program. Cota and Memorial Sloan Kettering will also collaborate on advanced analytics to produce more precise and consistent classifications for cancer.
Paul Sabbatini, deputy physician-in-chief for clinical research at Memorial Sloan Kettering, says in a Cota statement that the collaboration, “will help us have a more robust understanding of the components that make up a patient’s diagnosis and care pathway. This organized and analyzed data will help our physicians practice more efficiently, optimizing the care a patient receives based on a variety of characteristics and ultimately can improve outcomes for all cancer patients as this knowledge is shared.”
The company’s president Scott Paddock adds, “the CNA system offers the tools for providers and payers to deliver value-based care, providing the data to avoid adverse variance — too much or too little care — thus optimizing clinical outcomes for each patient and reducing the total cost of care for the population served. Researchers can also leverage a deeper and richer set of real-world evidence to fuel more efficient and effective development of new cancer treatments.”
Cota engages in a number of collaborations for analytics solutions involving cancer. In April 2015, Science & Enterprise reported on a partnership between Cota and Caris Life Sciences in Texas to combine their data on the chemical makeup of cancer patients with clinical outcomes information to create better profiles of cancer tumors and identify more personalized therapies.
More from Science & Enterprise:
- Alliance to Develop Rare Cancer Preclinical Models
- FDA Clears Algorithm-Assisted Cancer Diagnosis
- Skin Health Data Collected by App Offered for Research
- Alliance to Study Brain Tumor Precision Diagnostics
- Grid Computing Harnessed for Childhood Cancer Research
* * *
RSS - Posts
You must be logged in to post a comment.